里程碑时刻！复邦德®144周SPRINT研究入选欧洲艾滋病大会口头报告

· 艾诺韦林固定制剂对青年 HIV-1 感染者的疗效和安全性：RACER 和 SPRINT 研究（两项随机、阳性药物对照的 Ⅲ 期试验）的汇总分析

#eP129: Efficacy, and safety of ainuovirine plus lamivudine, and tenofovir DF in young people with HIV-1: pooled analyses of RACER, and SPRINT studies, two randomized, active-controlled phase 3 trials

· 基于艾诺韦林的抗逆转录病毒疗法对女性 HIV-1 感染者的疗效和安全性：RACER 和 SPRINT 研究的汇总分析，这是两项多中心、随机、阳性药物对照的 Ⅲ 期试验

#eP130: Efficacy, and safety of ainuovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials

· 在HIV-1初治患者中，与基于依非韦伦的方案相比，艾诺韦林初始治疗方案可实现更高的病毒学抑制率——一项多中心、随机、阳性对照RACER试验研究关于预处理NNRTI耐药性的影响

#eP149: High virologic suppression in treatment-naïve people with HIV-1 on ainuovirine- versus efavirenz-based antiretroviral regimen as initial therapy: effect of pretreatment NNRTI resistance from RACER trial, a multi-center, randomized, active-controlled study

· 基于艾诺韦林的抗逆转录病毒方案改善HIV-1感染者动脉粥样硬化性心血管疾病风险相关血脂异常：来自SPRINT III期随机试验的144周结果

#eP267: Improved atherosclerotic cardiovascular disease risk-associated dyslipidemia strata in people with HIV-1 switching to ainuovirine based antiretroviral regimen: week 144 results from SPRINT, a randomized phase 3 trial

· 病毒学抑制的HIV-1感染者换用艾诺韦林复方制剂后甘油三酯-葡萄糖指数与胰岛素抵抗的长期变化：SPRINT研究后续144周开放标签结果

#eP274: Long-term changes in triglyceride-glucose index and insulin resistance in virologically suppressed people with HIV-1 switching to ainuovirine coformulated with lamivudine, and tenofovir DF: 144-week, open-label results from the SPRINT post-study

· 换用基于艾诺韦林的方案为HIV-1感染者带来长期血脂代谢获益：SPRINT扩展研究144周结果

#eP275: Long-term Lipid Metabolism Benefits of Switching to Ainuovirine based Regimen in People with HIV-1: 144-Week Results from the SPRINT Extensional Post-study

· 基于艾诺韦林的抗逆转录病毒方案对HIV感染者肾功能保持良好：随机Ⅲ期试验SPRINT研究144周结果

#eP285: Preserved renal function in PWH on ainuovirine-based antiretroviral regimen: week 144 results from SPRINT study, a randomized phase 3 trial